摘要
目的:检测SQCC-m GC中的致癌基因突变,以期指导肺鳞癌靶向治疗患者的筛选。方法:用HRM技术检测100例病理确诊的肺鳞癌标本中肺癌驱动基因。结果:与单纯SQCC组相比,SQCC-m GC组带有已知致癌基因突变的比例更高(23.3%vs 4.3%),差异具有统计学意义(P<0.001)。结论:EGFR、ALK或KRAS基因突变在SQCC-m GC中出现频率较高,在治疗前对SQCC-m GC患者进行致癌基因突变检测,有助于筛选靶向治疗的潜在受益人群。
Objective:To detect EGFR,KRAS,ALK gene mutation in patients with contains a small amount of lung squamous cell carcinoma adenocarcinoma component (SQCC-mGC).Methods:One hundred surgically resected lung squamous cell carcinoma(SQCC) specimens were pathologically subdivided into SQCC group in 70 and SQCC-mGC group in 30.The EGFR,KRAS and ALK gene mutation were detected with HRM.Results:There was a significant difference between SQCC-mGC group and SQCC goup in rate of gene mutations (23.3% vs 4.3 %,P < 0.001).Conclusion:The rate of EGFR,KRAS and ALK gene mutation was remarkably higher in group SQCC-mGC than that of group SQCC.To detect these gene mutation before the initiation of treatment might be benefited to those patients with SQCC-mGC.
出处
《现代肿瘤医学》
CAS
2015年第14期1988-1989,共2页
Journal of Modern Oncology
基金
陕西省社发公关项目(编号:2009k12-01)
关键词
基因突变
肺鳞腺状细胞癌
HRM技术
gene mutation
squamous cell carcinoma
high resolution melting